$42.04+0.58 (+1.40%)
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.
Axogen, Inc. in the Healthcare sector is trading at $42.04. Wall Street consensus targets $50.78 (9 analysts), implying a +20.8% move over the next 12 months. The stock is currently near its 52-week high of $45.83, remaining 42.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intende...
Eli Lilly leads three health care stocks to watch as the market appears to be rotating into medicals. Google stock is finding key support too.
AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance.
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. Speaking during a company event, Dale said he w
Shareholders of Axogen, Inc. ( NASDAQ:AXGN ) will be pleased this week, given that the stock price is up 12% to...
Axogen Inc (AXGN) reports a robust 26.6% revenue increase in Q1 2026, despite facing higher operating costs and a significant net loss.